Search

Background Living donor liver transplantation (LDLT) for Budd-Chiari syndrome (BCS) has been reported with <10 inferior vena cava (IVC) replacements with vascular/synthetic graft. The goal of this study was to review outcomes of LDLT for BCS at our center, with an emphasis on surgical techniques and postoperative anticoagulation therapy. Methods Between October 2011 and December 2015, a total of 1027 LDLTs were performed. Nine of these patients had BCS. We analyzed their etiologies, operative details, postoperative complications, and outcomes. Results The indication was chronic liver disease for all patients. Two patients required retrohepatic IVC replacement with a polytetrafluoroethylene graft due to severe adhesions and thrombosis, respectively. One patient required V-Y plasty for suprahepatic IVC narrowing. Five patients had portal venous thrombosis, 3 treated by thrombectomy, and 1 by renoportal anastomosis. The mean follow-up time was 18 ± 16 months. Only 1 early death occurred due to sepsis. The anticoagulation therapy involved heparin infusion from postoperative day 1, conversion to low-molecular-weight-heparin on postoperative days 3 to 6, followed by warfarin (postoperative days 9–16 to maintain an international normalized ratio of 2–3 long term), along with low-dose aspirin for 6 months. There was no recurrence of thrombosis. Conclusions LDLT for BCS is well documented in literature. Prevention of recurrent thrombosis depends on meticulous surgical technique, perfect and wide outflow anastomoses, and a strict anticoagulation protocol. A synthetic (polytetrafluoroethylene) graft for IVC interposition is a safe and feasible option for reconstruction with good results. Low-dose aspirin with low-molecular-weight-heparin later converted to warfarin provides excellent results and prevents recurrence of thrombosis. [ABSTRACT FROM AUTHOR]

B Background: b Prevalence of hepatolithiasis is common in South-East Asia, which mainly presented as recurrent pyogenic cholangitis, acute cholangitis and accredited a risk factor for cholangiocarcinoma. In comparison with other series of non-operative management, hepatectomy had higher stone clearance and reduced recurrence of stone and cholangitis, and reduced the risk of cholangiocarcinoma. B Conclusion: b Hepatectomy for hepatolithiasis has highest stone clearance and lowest recurrent cholangitis rates. [Extracted from the article]

B Background: b Prevalence of hepatolithiasis is common in South-East Asia, which mainly presented as recurrent pyogenic cholangitis, acute cholangitis and accredited a risk factor for cholangiocarcinoma. In comparison with other series of non-operative management, hepatectomy had higher stone clearance and reduced recurrence of stone and cholangitis, and reduced the risk of cholangiocarcinoma. B Conclusion: b Hepatectomy for hepatolithiasis has highest stone clearance and lowest recurrent cholangitis rates. [Extracted from the article]